Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its innovative immu... Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. Mehr anzeigen
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors PR Newswire HOLON, Israel, Jan. 8...
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies PR...
Compugen Reports Third Quarter 2024 Results PR Newswire HOLON, Israel, Nov. 12, 2024 Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with...
Compugen to Participate in Stifel 2024 Healthcare Conference PR Newswire HOLON, Israel, Nov. 11, 2024 HOLON, Israel, Nov. 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a...
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 PR Newswire HOLON, ISRAEL...
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 PR Newswire HOLON, Israel, Oct. 29, 2024 HOLON, Israel, Oct. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq:...
Compugen to Present New Clinical Data at SITC 2024 PR Newswire HOLON, Israel, Oct. 7, 2024 HOLON, Israel, Oct. 7, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.03 | -1.79640718563 | 1.67 | 1.67 | 1.52 | 506886 | 1.59409437 | CS |
| 4 | 0.0188 | 1.15963483839 | 1.6212 | 1.6999 | 1.44 | 429499 | 1.56855426 | CS |
| 12 | -0.08 | -4.6511627907 | 1.72 | 1.84 | 1.35 | 373348 | 1.58766429 | CS |
| 26 | -0.12 | -6.81818181818 | 1.76 | 2.125 | 1.35 | 299704 | 1.69906645 | CS |
| 52 | -0.13 | -7.34463276836 | 1.77 | 3.0301 | 1.35 | 393640 | 2.05916591 | CS |
| 156 | -2.45 | -59.902200489 | 4.09 | 4.34 | 0.51 | 758887 | 1.79637617 | CS |
| 260 | -4.62 | -73.8019169329 | 6.26 | 19.9 | 0.51 | 933828 | 6.54229795 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
